Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 3

Status

Completed 3Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Carcinoma, Hepatocellular 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × tepotinib × Clear all
NCT01982955 2022-11-08

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
88 enrolled 45 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01988493 2022-08-24

Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
117 enrolled 30 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT02115373 2022-08-24

c-Met Second-Line Hepatocellular Carcinoma

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
66 enrolled 34 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡